NRx Pharmaceuticals Inc. (NRXP), a clinical-stage biopharmaceutical company, is gearing up for key milestones this year as it advances its lead drug candidate NRX-100.
NRX-100 (ketamine) is an intravenous formulation of ketamine in development for the treatment of patients with severe depression and acute suicidal ideation.
It's worth noting that Ketamine itself is not new - its history dates back more than five decades, when it was developed by Parke-Davis. Intravenous racemic ketamine was approved by the FDA in 1970 for use in diagnostic and surgical procedures. It is also used off label for several psychiatric conditions and other disorders.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.